Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Nov 24, 2023 7:40pm
165 Views
Post# 35752395

RE:RE:RE:Weight loss drug

RE:RE:RE:Weight loss drug

 

1- Obese people are high risk population(NAFLD/NASH) due to the fact that they have higher level of visceral fat so their relative reduction of liver fat is only relevant among overweight people as their placebo population were most likely also overweight.

2- NAFLD/ NASH are multi etiological conditions and excessive visceral fat is one of many number of reasons for conditions however lean people also can develop the condition due to many reason including but not exclusively the excessive visceral fat.

3- Although these weight loss drugs don't have high prevalence of side effects those adverse reactions are serious resulting in pancreatitis and obstruction of the digestive system. Considering NAFLD is now an epidemic condition a large number of obese patients will end up with those serious complications if and when these drugs are approved for the condition. 

4- It is obvious the all the propaganda about these weigh loss drugs are intended to support their absolutely unbelievable popularity and financially motivated despite the unfavourable benefit/risk equation among metabolically healthy overweight people. Crazy ac it is somehow the pharmaceutical companies unethically keep carry on with their manipulated narratives and can get away with anything...

<< Previous
Bullboard Posts
Next >>